Variation in collagenase Clostridium histolyticum practice patterns: a Survey of ISSM Members

T. A. Masterson, A. Galante, M. Butaney, A. Pastuszak, H. Sadeghi-Nejad, Ranjith Ramasamy

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Collagenase clostridium histolyticum (CCH, Xiaflex, Xiapex) is the only FDA-approved medication for treatment of Peyronie’s disease. It is unclear how practitioners actually use CCH in their own practices. The objectives of the study were: (1) to identify variability in practice patterns for CCH among practitioners, (2) to assess adherence to the package insert instructions, and (3) to evaluate whether provider satisfaction was associated with adherence to instructions. A 30-question online survey was distributed to 1270 members of the International Society for Sexual Medicine (ISSM) from the EU, USA, Canada and Australia. Of the 30 questions, 10 survey questions had only one response consistent with the CCH package insert recommendations. An “adherence” score was calculated for each survey participant depending on how many of these questions were answered correctly. The average adherence scores of various groups were compared using a student’s t-test. A chi-squared test was used to determine association between categorical variables. Of 202 total responses, 132 practitioners reported using CCH out of 1270 ISSM members from countries where CCH is available (10.4% response rate). Practitioners from outside the USA were more likely to be satisfied with CCH (p = 0.006), and more experienced users (>20 uses) were more likely to be satisfied than less experienced users (<10 uses) (p = 0.046). Satisfied users of CCH did not have significantly different adherence scores than non-satisfied users. Even though 67% of practitioners believed they followed the package insert guidelines, only 11% adhered to all the recommendations evaluated by the survey. Treatment adherence to package insert guidelines does not appear to be associated with provider satisfaction. We believe there is utility in seeing a snapshot of these practice patterns so practitioners may feel more comfortable adapting their own practice in light of newer data supporting alternative administration methods.

Original languageEnglish (US)
JournalInternational Journal of Impotence Research
DOIs
StatePublished - Jan 1 2019

Fingerprint

Microbial Collagenase
Product Labeling
Medicine
Guidelines
Penile Induration
Canada
Students
Surveys and Questionnaires
Therapeutics

ASJC Scopus subject areas

  • Urology

Cite this

Variation in collagenase Clostridium histolyticum practice patterns : a Survey of ISSM Members. / Masterson, T. A.; Galante, A.; Butaney, M.; Pastuszak, A.; Sadeghi-Nejad, H.; Ramasamy, Ranjith.

In: International Journal of Impotence Research, 01.01.2019.

Research output: Contribution to journalArticle

@article{1abf96e241b947448c8e4943e4ed3e8f,
title = "Variation in collagenase Clostridium histolyticum practice patterns: a Survey of ISSM Members",
abstract = "Collagenase clostridium histolyticum (CCH, Xiaflex, Xiapex) is the only FDA-approved medication for treatment of Peyronie’s disease. It is unclear how practitioners actually use CCH in their own practices. The objectives of the study were: (1) to identify variability in practice patterns for CCH among practitioners, (2) to assess adherence to the package insert instructions, and (3) to evaluate whether provider satisfaction was associated with adherence to instructions. A 30-question online survey was distributed to 1270 members of the International Society for Sexual Medicine (ISSM) from the EU, USA, Canada and Australia. Of the 30 questions, 10 survey questions had only one response consistent with the CCH package insert recommendations. An “adherence” score was calculated for each survey participant depending on how many of these questions were answered correctly. The average adherence scores of various groups were compared using a student’s t-test. A chi-squared test was used to determine association between categorical variables. Of 202 total responses, 132 practitioners reported using CCH out of 1270 ISSM members from countries where CCH is available (10.4{\%} response rate). Practitioners from outside the USA were more likely to be satisfied with CCH (p = 0.006), and more experienced users (>20 uses) were more likely to be satisfied than less experienced users (<10 uses) (p = 0.046). Satisfied users of CCH did not have significantly different adherence scores than non-satisfied users. Even though 67{\%} of practitioners believed they followed the package insert guidelines, only 11{\%} adhered to all the recommendations evaluated by the survey. Treatment adherence to package insert guidelines does not appear to be associated with provider satisfaction. We believe there is utility in seeing a snapshot of these practice patterns so practitioners may feel more comfortable adapting their own practice in light of newer data supporting alternative administration methods.",
author = "Masterson, {T. A.} and A. Galante and M. Butaney and A. Pastuszak and H. Sadeghi-Nejad and Ranjith Ramasamy",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41443-019-0126-y",
language = "English (US)",
journal = "International Journal of Impotence Research",
issn = "0955-9930",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Variation in collagenase Clostridium histolyticum practice patterns

T2 - a Survey of ISSM Members

AU - Masterson, T. A.

AU - Galante, A.

AU - Butaney, M.

AU - Pastuszak, A.

AU - Sadeghi-Nejad, H.

AU - Ramasamy, Ranjith

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Collagenase clostridium histolyticum (CCH, Xiaflex, Xiapex) is the only FDA-approved medication for treatment of Peyronie’s disease. It is unclear how practitioners actually use CCH in their own practices. The objectives of the study were: (1) to identify variability in practice patterns for CCH among practitioners, (2) to assess adherence to the package insert instructions, and (3) to evaluate whether provider satisfaction was associated with adherence to instructions. A 30-question online survey was distributed to 1270 members of the International Society for Sexual Medicine (ISSM) from the EU, USA, Canada and Australia. Of the 30 questions, 10 survey questions had only one response consistent with the CCH package insert recommendations. An “adherence” score was calculated for each survey participant depending on how many of these questions were answered correctly. The average adherence scores of various groups were compared using a student’s t-test. A chi-squared test was used to determine association between categorical variables. Of 202 total responses, 132 practitioners reported using CCH out of 1270 ISSM members from countries where CCH is available (10.4% response rate). Practitioners from outside the USA were more likely to be satisfied with CCH (p = 0.006), and more experienced users (>20 uses) were more likely to be satisfied than less experienced users (<10 uses) (p = 0.046). Satisfied users of CCH did not have significantly different adherence scores than non-satisfied users. Even though 67% of practitioners believed they followed the package insert guidelines, only 11% adhered to all the recommendations evaluated by the survey. Treatment adherence to package insert guidelines does not appear to be associated with provider satisfaction. We believe there is utility in seeing a snapshot of these practice patterns so practitioners may feel more comfortable adapting their own practice in light of newer data supporting alternative administration methods.

AB - Collagenase clostridium histolyticum (CCH, Xiaflex, Xiapex) is the only FDA-approved medication for treatment of Peyronie’s disease. It is unclear how practitioners actually use CCH in their own practices. The objectives of the study were: (1) to identify variability in practice patterns for CCH among practitioners, (2) to assess adherence to the package insert instructions, and (3) to evaluate whether provider satisfaction was associated with adherence to instructions. A 30-question online survey was distributed to 1270 members of the International Society for Sexual Medicine (ISSM) from the EU, USA, Canada and Australia. Of the 30 questions, 10 survey questions had only one response consistent with the CCH package insert recommendations. An “adherence” score was calculated for each survey participant depending on how many of these questions were answered correctly. The average adherence scores of various groups were compared using a student’s t-test. A chi-squared test was used to determine association between categorical variables. Of 202 total responses, 132 practitioners reported using CCH out of 1270 ISSM members from countries where CCH is available (10.4% response rate). Practitioners from outside the USA were more likely to be satisfied with CCH (p = 0.006), and more experienced users (>20 uses) were more likely to be satisfied than less experienced users (<10 uses) (p = 0.046). Satisfied users of CCH did not have significantly different adherence scores than non-satisfied users. Even though 67% of practitioners believed they followed the package insert guidelines, only 11% adhered to all the recommendations evaluated by the survey. Treatment adherence to package insert guidelines does not appear to be associated with provider satisfaction. We believe there is utility in seeing a snapshot of these practice patterns so practitioners may feel more comfortable adapting their own practice in light of newer data supporting alternative administration methods.

UR - http://www.scopus.com/inward/record.url?scp=85061492587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061492587&partnerID=8YFLogxK

U2 - 10.1038/s41443-019-0126-y

DO - 10.1038/s41443-019-0126-y

M3 - Article

AN - SCOPUS:85061492587

JO - International Journal of Impotence Research

JF - International Journal of Impotence Research

SN - 0955-9930

ER -